- 商品介绍
- 规格参数
- 包装参数
Biochem/physiol Actions
Somatostatin (SRIF) eptidomimetic with high affinity for somatostatin receptor subtypes STT1/2/3/5 and in vivo efficacy for suppressing GH secretion.
Pasireotide (SOM230) is a somatostatin (somatotropin release inhibiting factor, SRIF) eptidomimetic with high affinity for somatostatin receptor subtypes STT1/2/3/5 (IC50 = 9.3/1/1.5/0.16 nM), but not STT4 (IC50 > 1 μM). SOM230 potently inhibits the growth hormone (GH) releasing hormone (GHRH)-induced GH release in primary rat pituitary cultures (IC50 = 0:4 nM) and suppresses the secretion of GH, insulin and glucagon in rats in vivo (ED50 in μg/kg post 1h administration via s.c. = 0.22, 3.4, 74, respectively; GH ED50 post 6h = 5.5 μg/kg).
Disclaimer
Hygroscopic
| Quality Segment | 100 |
| assay | ≥95% (HPLC) |
| form | (Powder or Lyophilized powder or film) |
| storage condition | desiccated |
| color | white to off-white |
| storage temp. | -10 to -25°C |
| 长度(mm) | |
| 宽度(mm) | |
| 高度(mm) | |
| 重量(kg) |
-
¥ 1683.78
-
询价
-
询价
-
¥ 1451.54
-
¥ 4173.75
-
询价
-
¥ 3275.78
-
询价
-
询价
-
¥ 5725.45
-
¥ 2883.61
-
询价
-
询价
-
¥ 14407.09
-
¥ 2268.97
-
¥ 4011.97
-
¥ 8137.12
-
¥ 1476.40
-
¥ 9909.51
-
¥ 4614.63
微信小程序
7X24小时在线咨询